Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $1.2 billion.

  • Harmony Biosciences Holdings' Liabilities and Shareholders Equity rose 3017.7% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 2688.02%. This contributed to the annual value of $999.2 million for FY2024, which is 2313.79% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Liabilities and Shareholders Equity stood at $1.2 billion, which was up 3017.7% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Liabilities and Shareholders Equity peaked at $1.2 billion during Q3 2025, and registered a low of $337.3 million during Q1 2021.
  • In the last 5 years, Harmony Biosciences Holdings' Liabilities and Shareholders Equity had a median value of $760.2 million in 2023 and averaged $730.4 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Liabilities and Shareholders Equity skyrocketed by 149.13% in 2021 and then surged by 6453.01% in 2022.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Liabilities and Shareholders Equity stood at $433.4 million in 2021, then skyrocketed by 55.47% to $673.9 million in 2022, then increased by 20.42% to $811.4 million in 2023, then grew by 23.14% to $999.2 million in 2024, then grew by 20.92% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.